This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Spectranetics Achieves Second Quarter Revenue Of $39.5 Million

13% Increase Over Q2 2012

Raises 2013 Revenue Outlook

COLORADO SPRINGS, Colo., July 24, 2013 (GLOBE NEWSWIRE) -- The Spectranetics Corporation (Nasdaq:SPNC) today reported financial results for the three and six months ended June 30, 2013. Highlights of the quarter (all compared with the quarter ended June 30, 2012) include:
  • Vascular Intervention revenue growth of 8% as reported (9% growth on a constant currency basis 1), led by U.S. peripheral atherectomy revenue growth of 19%
  • Lead Management revenue growth of 11%
  • U.S. revenue increased 11% to $32.3 million; International revenue increased 22% to $7.1 million
  • Completed $92 million common stock offering
  • 2013 revenue outlook raised from $153.0 - $155.5 million to $155.5 - $157.5 million

"The second quarter of 2013 reflects consistent double digit revenue growth, driven by our focus areas," said President and Chief Executive Officer, Scott Drake. "We placed 48 lasers this quarter, surpassing our previous record from the fourth quarter 2012 of 42 laser placements, which bodes well for future revenue growth. We have improved enrollment in EXCITE ISR, with 184 patients currently enrolled, bringing us closer to our goal of achieving the in-stent restenosis indication and proving clinical superiority. Our long term objective is unchanged - accelerating revenue growth and gross margin expansion yielding meaningful operating leverage over time."

Revenue for the three months ended June 30, 2013 rose 13% both on an as reported and a constant currency basis, to $39.5 million, from $35.0 million in the 2012 period. Vascular Intervention revenue increased 8% to $18.9 million (9% constant currency); Lead Management revenue increased 11% to $15.1 million; and laser system, service and other revenue increased 34% to $5.5 million.

Net loss for the three months ended June 30, 2013 was $728,000, or a loss of $0.02 per diluted share, compared with net income of $636,000, or $0.02 per diluted share, for the three months ended June 30, 2012. Earnings before interest, taxes, depreciation, amortization, acquisition-related costs and contingent consideration expense, and the medical device excise tax ("Adjusted EBITDA") 2 was $2.7 million for the three months ended June 30, 2013 compared with $3.3 million for the three months ended June 30, 2012.

Year-To-Date Financial Results

Revenue for the six months ended June 30, 2013 rose 13% (both as reported and on a constant currency basis) to $77.1 million, from $68.3 million for the six months ended June 30, 2012. Vascular Intervention revenue increased 7% to $36.1 million, Lead Management revenue increased 16% to $30.2 million, and laser system, service and other revenue increased 27% to $10.9 million.

1 of 5

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.79 0.10%
FB $101.98 0.07%
GOOG $682.32 -0.12%
TSLA $151.04 0.38%
YHOO $27.04 1.00%


Chart of I:DJI
DOW 15,973.84 +313.66 2.00%
S&P 500 1,864.78 +35.70 1.95%
NASDAQ 4,337.5120 +70.6750 1.66%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs